Naoyuki Taniguchi Selected Research

beta-D-Galactoside alpha 2-6-Sialyltransferase

9/2010	Involvement of ST6Gal I in the biosynthesis of a unique human colon cancer biomarker candidate, alpha2,6-sialylated blood group type 2H (ST2H) antigen.
5/2009	Molecular insights into beta-galactoside alpha2,6-sialyltransferase secretion in vivo.
3/2005	In vivo cleavage of alpha2,6-sialyltransferase by Alzheimer beta-secretase.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Naoyuki Taniguchi Research Topics

Disease

69	Neoplasms (Cancer) 11/2022 - 02/2002
21	Neoplasm Metastasis (Metastasis) 01/2021 - 02/2002
17	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 03/2005
15	Hepatocellular Carcinoma (Hepatoma) 12/2017 - 08/2002
14	Emphysema 01/2021 - 11/2005
11	Inflammation (Inflammations) 01/2021 - 03/2002
10	Carcinogenesis 01/2022 - 04/2002
10	Carcinoma (Carcinomatosis) 10/2016 - 10/2003
9	Chronic Obstructive Pulmonary Disease (COPD) 01/2021 - 07/2012
8	Atherosclerosis 05/2012 - 03/2002
7	Stomach Neoplasms (Stomach Cancer) 10/2016 - 04/2002
7	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 04/2016 - 05/2003
6	Colonic Neoplasms (Colon Cancer) 09/2010 - 01/2004
5	Melanoma (Melanoma, Malignant) 10/2022 - 09/2007
5	Pancreatic Neoplasms (Pancreatic Cancer) 02/2013 - 03/2006
3	Lung Neoplasms (Lung Cancer) 01/2022 - 03/2004
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2021 - 01/2016
3	Colitis 03/2019 - 05/2015
3	Liver Cirrhosis (Hepatic Cirrhosis) 09/2012 - 10/2003
3	Neuroblastoma 01/2010 - 01/2006
3	Papillary Carcinoma 11/2008 - 10/2003
2	Congenital, Hereditary, and Neonatal Diseases and Abnormalities (Congenital Disorders) 11/2022 - 10/2005
2	Thrombosis (Thrombus) 01/2021 - 11/2012
2	Diabetes Complications 11/2019 - 11/2012
2	Experimental Melanoma 01/2019 - 02/2002
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2018 - 01/2016
2	Infections 05/2017 - 11/2002
2	Demyelinating Diseases (Demyelinating Disease) 01/2017 - 06/2013
2	Breast Neoplasms (Breast Cancer) 11/2016 - 11/2013
2	Nervous System Diseases (Neurological Disorders) 11/2016 - 01/2004
2	Disease Progression 04/2014 - 07/2012
2	Acute Coronary Syndrome 10/2013 - 11/2012

Drug/Important Bio-Agent (IBA)

51	Polysaccharides (Glycans)IBA 11/2022 - 07/2003
32	Proteins (Proteins, Gene)FDA Link 10/2022 - 01/2002
25	EnzymesIBA 01/2022 - 01/2002
15	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2006
15	GlycosyltransferasesIBA 01/2022 - 05/2002
15	OligosaccharidesIBA 01/2015 - 02/2002
14	LectinsIBA 01/2022 - 02/2002
14	FucoseIBA 01/2021 - 11/2002
13	alpha-1,6-mannosylglycoprotein beta 1,6-N-acetylglucosaminyltransferaseIBA 01/2018 - 01/2004
12	Glycoproteins (Glycoprotein)IBA 01/2021 - 05/2002
11	Biological ProductsIBA 01/2021 - 05/2002
10	Amyloid (Amyloid Fibrils)IBA 01/2022 - 03/2005
10	Tumor Biomarkers (Tumor Markers)IBA 01/2015 - 06/2006
8	SugarsIBA 01/2021 - 09/2007
7	AsparagineIBA 01/2022 - 03/2004
7	Matrix Metalloproteinases (MMPs)IBA 01/2017 - 11/2005
7	Cadherins (E-Cadherin)IBA 10/2016 - 05/2008
7	Peptides (Polypeptides)IBA 02/2015 - 03/2005
5	IntegrinsIBA 01/2022 - 05/2008
5	NucleotidesIBA 01/2021 - 07/2010
5	Pharmaceutical PreparationsIBA 12/2019 - 02/2009
5	SmokeIBA 01/2017 - 06/2007
5	Peptide Hydrolases (Proteases)FDA Link 01/2016 - 03/2005
5	Superoxide Dismutase-1IBA 02/2014 - 01/2002
5	alpha-Fetoproteins (alpha-Fetoprotein)IBA 10/2010 - 10/2006
4	Keratan SulfateIBA 10/2022 - 01/2017
4	FucosyltransferasesIBA 01/2021 - 01/2015
4	Messenger RNA (mRNA)IBA 05/2017 - 04/2002
4	LigandsIBA 05/2012 - 01/2004
4	AcetylglucosamineIBA 01/2011 - 05/2006
3	DisaccharidesIBA 01/2021 - 01/2017
3	TransferasesIBA 01/2021 - 02/2006
3	Pancreatic Elastase (Elastase)IBA 01/2017 - 07/2012
3	Sialic Acid Binding Immunoglobulin-like LectinsIBA 01/2017 - 02/2013
3	AntioxidantsIBA 01/2016 - 01/2002
3	ZincIBA 01/2015 - 01/2002
3	Cell Adhesion MoleculesIBA 03/2013 - 11/2002
3	RNA (Ribonucleic Acid)IBA 03/2013 - 02/2005
3	beta-D-Galactoside alpha 2-6-SialyltransferaseIBA 09/2010 - 03/2005
3	Guanosine Diphosphate (GDP)IBA 07/2010 - 11/2002
3	Uridine Diphosphate (UDP)IBA 07/2010 - 02/2002
3	Monoclonal AntibodiesIBA 02/2009 - 01/2005
3	HaptoglobinsIBA 05/2008 - 08/2002
3	PhytohemagglutininsIBA 09/2007 - 03/2004
3	matriptaseIBA 05/2006 - 05/2002
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022 - 04/2002
2	N-AcetylglucosaminyltransferasesIBA 01/2021 - 03/2013
2	GlycolipidsIBA 01/2021 - 01/2004
2	Advanced Glycation End ProductsIBA 11/2019 - 06/2016
2	Dextrans (Dextran)FDA Link 03/2019 - 05/2015
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018 - 08/2004
2	Guanosine Diphosphate Fucose (GDP Fucose)IBA 12/2017 - 12/2007
2	AntibodiesIBA 01/2017 - 11/2002
2	CytokinesIBA 01/2017 - 01/2016
2	CuprizoneIBA 01/2017 - 06/2013
2	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 10/2016 - 03/2004
2	Reactive Nitrogen SpeciesIBA 04/2016 - 03/2002
2	Reactive Oxygen Species (Oxygen Radicals)IBA 04/2016 - 02/2003
2	GlycoconjugatesIBA 01/2016 - 10/2005
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 02/2014 - 01/2002
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2014 - 07/2009
2	Tissue Inhibitor of Metalloproteinase-1IBA 12/2013 - 01/2008
2	Neuregulin-1 (Neuregulin 1)IBA 11/2013 - 03/2007
2	Indicators and Reagents (Reagents)IBA 10/2013 - 11/2012
2	DNA (Deoxyribonucleic Acid)IBA 03/2013 - 03/2006
2	AntigensIBA 02/2013 - 09/2010
2	Lipoproteins (Lipoprotein)IBA 05/2012 - 06/2002

Therapy/Procedure

7	Therapeutics 01/2022 - 02/2010